Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by dardanion Aug 03, 2016 9:19am
71 Views
Post# 25105595

RE:RE:RE:Competition...

RE:RE:RE:Competition...
All that needs to be said has been said. Investors don't need any more elaborate theories expounded.  Now it's up to Roger to make it happen and I might add, before the company reaches a fast approaching cash crunch. Debating how compelling theory is won't move the share price yardsticks. The market needs more in the way of substance to go on. Let's be honest, the risk has not lessened by the use of DFOC technology if anything it has increased since it makes the procedure they hope to use on patients a lot more intricate than shareholders first suspected. More complexity usually means more chances that something can go wrong. The DFOC technology is still in its unproven infancy and should be viewed as such. Modern cars are great until all the electronic bells and whistles start to fail. First things first, we have to wait and see if Health Canada is even satisfied with TLT's 700 page response to their concerns?
Bullboard Posts